Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics

Monoclonal antibody therapies have significantly improved treatment outcomes for patients with severe asthma; however, a significant disease burden remains. Available biologic treatments, including anti-immunoglobulin (Ig)E, anti-interleukin (IL)-5, anti-IL-5Rα and anti-IL-4Rα, reduce exacerbation r...

Descripción completa

Detalles Bibliográficos
Autores principales: Porsbjerg, Celeste M., Sverrild, Asger, Lloyd, Clare M., Menzies-Gow, Andrew N., Bel, Elisabeth H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676874/
https://www.ncbi.nlm.nih.gov/pubmed/32586879
http://dx.doi.org/10.1183/13993003.00260-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676874/
https://www.ncbi.nlm.nih.gov/pubmed/32586879
http://dx.doi.org/10.1183/13993003.00260-2020

Ejemplares similares